Peter Duewell

Peter Duewell

Auto-generated profile, based on publicly available information

Peter Duewell

Institute of Innate Immunity, Medical Faculty, University of Bonn, Bonn, Germany

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2010 in Nature
Verified
Journal Article
Open access
PDF file
PDPeter Duewell
Peter Duewell
Hajime KonoHajime Kono
Hajime Kono
KRKatey J. Rayner
Katey J. Rayner
CSCherilyn M. Sirois
Cherilyn M. Sirois
GVGregory Vladimer
Gregory Vladimer
ELEicke Latz
Eicke Latz
A study in atherosclerosis-prone (apolipoprotein E-deficient) mice on a high cholesterol diet shows that small cholesterol crystals appear in the earliest stages of atherogenesis, and that these crystals can activate the NLRP3 inflammasome in phagocytes. This suggests that therapeutic strategies that reduce cholesterol crystal deposition or block the inflammasome pathway may have anti-atherosclerotic activity. During atherosclerosis, crystals of cholesterol accumulate in atherosclerotic plaques. But are they a consequence or a cause of the inflammation associated with the disease? Here it is shown that small cholesterol crystals appear early in the development of atherosclerosis, and that they act as an endogenous danger signal, causing inflammation by activating the NLRP3 inflammasome pathway. Cholesterol crystals thus seem to be an early cause, rather than a late consequence, of inflammation. The inflammatory nature of atherosclerosis is well established but the agent(s) that incite inflammation in the artery wall remain largely unknown. Germ-free animals are susceptible to atherosclerosis, suggesting that endogenous substances initiate the inflammation1. Mature atherosclerotic lesions contain macroscopic deposits of cholesterol crystals in the necrotic core, but their appearance late in atherogenesis had been thought to disqualify them as primary inflammatory stimuli. However, using a new microscopic technique, we revealed that minute cholesterol crystals are present in early diet-induced atherosclerotic lesions and that their appearance in mice coincides with the first appearance of inflammatory cells. Other crystalline substances can induce inflammation by stimulating the caspase-1-activating NLRP3 (NALP3 or cryopyrin) inflammasome2,3, which results in cleavage and secretion of interleukin (IL)-1 family cytokines. Here we show that cholesterol crystals activate the NLRP3 inflammasome in phagocytes in vitro in a process that involves phagolysosomal damage. Similarly, when injected intraperitoneally, cholesterol crystals induce acute inflammation, which is impaired in mice deficient in components of the NLRP3 inflammasome, cathepsin B, cathepsin L or IL-1 molecules. Moreover, when mice deficient in low-density lipoprotein receptor (LDLR) were bone-marrow transplanted with NLRP3-deficient, ASC (also known as PYCARD)-deficient or IL-1α/β-deficient bone marrow and fed on a high-cholesterol diet, they had markedly decreased early atherosclerosis and inflammasome-dependent IL-18 levels. Minimally modified LDL can lead to cholesterol crystallization concomitant with NLRP3 inflammasome priming and activation in macrophages. Although there is the possibility that oxidized LDL activates the NLRP3 inflammasome in vivo, our results demonstrate that crystalline cholesterol acts as an endogenous danger signal and its deposition in arteries or elsewhere is an early cause rather than a late consequence of inflammation. These findings provide new insights into the pathogenesis of atherosclerosis and indicate new potential molecular targets for the therapy of this disease.

1 January 2018 in Cell
Verified
Journal Article
Closed access
ACAnette Christ
Anette Christ
PGPatrick Günther
Patrick Günther
MLMario A.R. Lauterbach
Mario A.R. Lauterbach
PDPeter Duewell
Peter Duewell
DBDebjani Biswas
Debjani Biswas
ELEicke Latz
Eicke Latz

4 May 2010 in Gut
Verified
Journal Article
Closed access
PDF file
CBChristian Bauer
Christian Bauer
PDPeter Duewell
Peter Duewell
CMChristine Mayer
Christine Mayer
HLHans Anton Lehr
Hans Anton Lehr
KFKate Fitzgerald
Kate Fitzgerald
MSMax Schnurr
Max Schnurr
Background: The proinflammatory cytokines interleukin 1β (IL-1β) and IL-18 are central players in the pathogenesis of inflammatory bowel disease (IBD). In response to a variety of microbial components and crystalline substances, both cytokines are processed via the caspase-1-activating multiprotein complex, the NLRP3 inflammasome. Here, the role of the NLRP3 inflammasome in experimental colitis induced by dextran sodium sulfate (DSS) was examined. Methods: IL-1β production in response to DSS was studied in macrophages of wild-type, caspase-1 −/− , NLRP3 −/− , ASC −/− , cathepsin B −/− or cathepsin L −/− mice. Colitis was induced in C57BL/6 and NLRP3 −/− mice by oral DSS administration. A clinical disease activity score was evaluated daily. Histological colitis severity and expression of cytokines were determined in colonic tissue. Results: Macrophages incubated with DSS in vitro secreted high levels of IL-1β in a caspase-1-dependent manner. IL-1β secretion was abrogated in macrophages lacking NLRP3, ASC or caspase-1, indicating that DSS activates caspase-1 via the NLRP3 inflammasome. Moreover, IL-1β secretion was dependent on phagocytosis, lysosomal maturation, cathepsin B and L, and reactive oxygen species (ROS). After oral administration of DSS, NLRP3 −/− mice developed a less severe colitis than wild-type mice and produced lower levels of proinflammatory cytokines in colonic tissue. Pharmacological inhibition of caspase-1 with pralnacasan achieved a level of mucosal protection comparable with NLRP3 deficiency. Conclusions: The NLRP3 inflammasome was identified as a critical mechanism of intestinal inflammation in the DSS colitis model. The NLRP3 inflammasome may serve as a potential target for the development of novel therapeutics for patients with IBD.

11 July 2014 in Cell Death & Differentiation
Verified
Journal Article
Closed access
PDP Duewell
P Duewell
ASA Steger
A Steger
HLH Lohr
H Lohr
HBH Bourhis
H Bourhis
HHH Hoelz
H Hoelz
MSM Schnurr
M Schnurr

1 December 2018 in Seminars in Immunology
Verified
Journal Article
Closed access
ELEicke Latz
Eicke Latz
PDPeter Duewell
Peter Duewell

14 March 2013 in Cancer Research
Verified
Journal Article
Open access
PDF file
JEJonathan Ellermeier
Jonathan Ellermeier
JWJiwu Wei
Jiwu Wei
PDPeter Duewell
Peter Duewell
SHSabine Hoves
Sabine Hoves
MSMareike R. Stieg
Mareike R. Stieg
MSMax Schnurr
Max Schnurr
Deregulated TGF-β signaling in pancreatic cancer promotes tumor growth, invasion, metastasis, and a potent immunosuppressive network. A strategy for disrupting this tumor-promoting pathway is silencing TGF-β by siRNA. By introducing a triphosphate group at the 5′ end of siRNA (ppp-siRNA), gene silencing can be combined with immune activation via the cytosolic helicase retinoic acid-inducible gene I (RIG-I), a ubiquitously expressed receptor recognizing viral RNA. We validated RIG-I as a therapeutic target by showing that activation of RIG-I in pancreatic carcinoma cells induced IRF-3 phosphorylation, production of type I IFN, the chemokine CXCL10, as well as caspase-9–mediated tumor cell apoptosis. Next, we generated a bifunctional ppp-siRNA that combines RIG-I activation with gene silencing of TGF-β1 (ppp-TGF-β) and studied its therapeutic efficacy in the orthotopic Panc02 mouse model of pancreatic cancer. Intravenous injection of ppp-TGF-β reduced systemic and tumor-associated TGF-β levels. In addition, it induced high levels of type I IFN and CXCL10 in serum and tumor tissue, systemic immune cell activation, and profound tumor cell apoptosis in vivo. Treatment of mice with established tumors with ppp-TGF-β significantly prolonged survival as compared with ppp-RNA or TGF-β siRNA alone. Furthermore, we observed the recruitment of activated CD8+ T cells to the tumor and a reduced frequency of CD11b+ Gr-1+ myeloid cells. Therapeutic efficacy was dependent on CD8+ T cells, whereas natural killer cells were dispensable. In conclusion, combing TGF-β gene silencing with RIG-I signaling confers potent antitumor efficacy against pancreatic cancer by breaking tumor-induced CD8+ T cell suppression. Cancer Res; 73(6); 1709–20. ©2013 AACR.